MediWound Ltd. (MDWD) Financial Analysis & Valuation | Quarter Chart
MediWound Ltd. (MDWD)
MDWDPrice: $17.27
Fair Value: 🔒
🔒score
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-t... more
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bi... more
Description
Shares
| Market Cap | $187.60M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | IL | CEO | Ofer Gonen |
| IPO Date | 2014-03-20 | CAGR | — |
| Employees | 111 | Website | www.mediwound.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
MDWD chart loading...
Fundamentals
Technicals
| Enterprise Value | $189.17M | P/E Ratio | -9.39 |
| Forward P/E | -7.88 | PEG Ratio | — |
| P/S Ratio | 507.28 | P/B Ratio | 499.04 |
| P/CF Ratio | -657.74 | P/FCF Ratio | -522.84 |
| EPS | $-1.84 | EPS Growth 1Y | -34.58% |
| EPS Growth 3Y | -49.27% | EPS Growth 5Y | -31.76% |
| Revenue Growth 1Y | 6.15% | Gross Margin | 0.18% |
| Operating Margin | -1.11% | Profit Margin | -1.42% |
| ROE | -0.97% | ROA | -0.42% |
| ROCE | -0.58% | Current Ratio | 1.48 |
| Quick Ratio | 1.35 | Cash Ratio | 1.12 |
| Debt/Equity | 0.4 | Interest Coverage | -1.74 |
| Altman Z Score | -3.12 | Piotroski Score | 2 |